ArticleResearch square2026
Surveillance Imaging in Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis Informing Surveillance Recommendations.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Imaging surveillance for high-stage (HS), regionally metastatic (RM), and unresectable (UR) cutaneous squamous cell carcinoma (CSCC) is not standardized, and evidence guiding post-treatment imaging is limited. Objective: To characterize imaging surveillance practices for HS, RM, and UR CSCC at a single high-volume cancer center and propose tailored surveillance protocols. Methods: Retrospective cohort study of patients with HS, RM, or UR CSCC discussed at a multidisciplinary tumor board (January 2021-November 2024). Results: For HS CSCC, CT of the regional nodal basin was most common (83.9%), typically every 6 months for 2 years (61.3%). RM CSCC most frequently underwent CT (64.7%) or PET/CT (35.3%), most commonly every 6 months for 3 years (67.6%). UR CSCC surveillance included CT (57.9%) and PET/CT (42.1%), most often every 3 months for year 1 and every 6 months for years 2-3 (52.6%). Conclusions and Relevance: Imaging surveillance practices for advanced CSCC varied by disease extent and treatment. Proposed surveillance recommendations include CT every 6 months for 2 years (HS), CT every 6 months for 3 years (RM), and CT or PET/CT every 3 months for year 1 then every 6 months in years 2-3 (UR). These findings reflect real-world practice and may inform development of structured surveillance protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.